Approved
consistent with the following terms of clearance: upon completion
of the first round of the survey ONDCP will provide OMB with a
report of survey findings and achieved response rates at each site;
consistent with the limitations of the study design, reporting of
survey results will indicate that the survey is a purposive,
non-probability sample of sentinel sights that is not
representative of the US as a whole or individual states or other
areas that were not surveyed; additionally comparisons with prior
iterations of the ADAM survey should include a discussion of
variability in the data set over time and differences in the
coverage areas of the original DOJ survey and the current ONDCP
ADAM survey.
Inventory as of this Action
Requested
Previously Approved
03/31/2010
36 Months From Approved
5,000
0
0
1,667
0
0
1,320,000
0
0
The Office of National Drug Control
Policys (ONDCPs) mission, since its authorization in 1988, has
been to establish the Nations drug control policy, to set
priorities for advancing that policy, and to identify and monitor
objective measures of that policys success. The original Arrestee
Drug Abuse Monitoring program (ADAM) was a critical source of data
for ONDCP in meeting its objectives, and its demise in 2003 left a
serious gap in accurate and timely information on trends in drug
use. The first ADAM data collection was instituted in 2000 as a
replacement for the Drug Use Forecasting program (DUF), which
employed a non-scientific sampling procedure to select primarily
felony arrestees in 23 urban areas throughout the country. The year
2000 revision of ADAM instituted a representative sampling strategy
among booked male arrestees in an expanded network of 35 sites. The
original OMB approval for this collection authorized 100,000
responses and a time burden of 62,500 hours (OMB control #
1121-0137). That authorization expired in 2005. With ADAM II, ONDCP
and its contractor, Abt Associates, Inc., will initiate a new data
collection that will replicate the ADAM methodology in order to
obtain data comparable to previously established trends. ADAM II
will implement two quarters of data collection in ten sentinel ADAM
sites to revive monitoring drug trends, with a particular focus on
obtaining valid and reliable information on methamphetamine use.
Representing minimal adjustments to the previously approved ADAM
survey, the ADAM II survey will collect data about drug use, drug
and alcohol dependency and treatment, and drug market participation
among booked male arrestees within 48 hours of arrest. Data
collection will take place across two back-to-back quarters in each
of 10 counties from a county-based representative sample of 250
male arrestees per quarter for a total of 500 arrestees annually
per site or a total of 5000 arrestees across sites annually.
Collection will occur in two cycles at each site to provide
estimates for two calendar quarters each year. One year of
collection will occur beginning April 1, 2007 and ending March 31,
2008. If additional data collection periods are optioned by ONDCP,
subsequent cycles of back-to-back data collection will occur
beginning April 1, 2008. Participation is voluntary and
confidential, and the procedures will include a personal interview
(lasting approximately 20 minutes) and collection of a urine
specimen. Though a convenience sample of female and juvenile
arrestees was a part of the previous ADAM program, those groups
will be excluded from this effort for the purposes of
economy.
This ICR requests approval for
a data collection using a survey instrument (w/minimal update
changes)of a previously approved collection (OMB Control #
1121-0137) for which approval has expired. The original OMB
approval authorized 100,000 responses and a time burden of 62,500
hours. That authorization expired in 2005. This ICR requests
significantly less responses and time burden than the original
effort (5,000 responses and 1,667 hours per year).
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
Appl Appr NIH Cert of Conf.pdf
Abstract-ADAM II OMB Final.doc
Arrestee Drug Abuse Monitoring (ADAM II)